BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

. Author manuscript; available in PMC: 2019 Apr 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2017 Dec 11;24(4):641–648. doi: 10.1016/j.bbmt.2017.12.774

Recommendations:

Efforts are needed to standardize immunophenotyping/immune profiling studies.
Further prospective studies are needed to better understand the association between immunophenotype/immune profiling and MRD status.
Further studies are needed to determine whether immunophenotyping/immune profiling can be used to predict risk of progression to myeloma.
Further studies are needed to determine the effect of maintenance therapy on the immunophenotype/immune profile.